Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

68
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
68
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

815
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
815
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

78
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
78
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

48
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
48
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

109
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
109
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

103
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
103

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study.

Clinical toxicology (Philadelphia, Pa.)·2026
Same author

Trends in ketamine-related emergency department presentations across European centres: a Euro-DEN Plus Study (2013-2023).

European journal of emergency medicine : official journal of the European Society for Emergency Medicine·2026
Same author

Editorial: Application of new approach methodologies in toxicological assessment of next-generation tobacco and nicotine products.

Frontiers in toxicology·2026
Same author

Beyond the High: A Narrative Review of the Chronic Complications of Recreational Ketamine Use.

British journal of hospital medicine (London, England : 2005)·2026
Same author

Recommendations from the Clinical Toxicology Recommendations Collaborative on the administration of activated charcoal in acute oral overdose.

Clinical toxicology (Philadelphia, Pa.)·2026
Same author

Mechanism of NanR transcriptional activation of sialic acid metabolism in <i>Streptococcus pneumoniae</i>.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Mar 9, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.2K

Outcomes from massive paracetamol overdose: a retrospective observational study.

Daniel J B Marks1,2, Paul I Dargan1,3, John R H Archer1,3

  • 1Department of Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, UK.

British Journal of Clinical Pharmacology
|December 22, 2016
PubMed
Summary

Massive paracetamol overdose increases organ injury risk, even with early acetylcysteine. A paracetamol concentration to threshold ratio (APAPpl:APAPt) ≥3 indicates higher risk, suggesting a need for enhanced treatment strategies in these patients.

Keywords:
acetylcysteinecoagulopathyhepatotoxicityoverdoseparacetamol

Related Experiment Videos

Last Updated: Mar 9, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.2K

Area of Science:

  • Toxicology
  • Pharmacology
  • Emergency Medicine

Background:

  • Standard acetylcysteine treatment for paracetamol overdose is weight-based.
  • The efficacy of this approach for massive overdoses has been questioned.
  • A need exists to evaluate alternative strategies for significant paracetamol ingestions.

Purpose of the Study:

  • To systematically compare outcomes in massive versus non-massive paracetamol overdoses.
  • To determine if the APAPpl:APAPt ratio is a useful assessment tool.
  • To guide the development of alternative treatment strategies for massive paracetamol overdose.

Main Methods:

  • Retrospective observational study of 545 patients with acute non-staggered paracetamol overdose (2005-2013).
  • Massive overdose defined as extrapolated 4-h plasma paracetamol concentrations >250 mg/L or ingestions ≥30 g.
  • Outcomes (liver/kidney injury, coagulopathy) assessed against dose, APAPpl:APAPt ratio, and time to acetylcysteine.

Main Results:

  • Ingestions ≥30 g correlated with higher peak aminotransferase and creatinine.
  • APAPpl:APAPt ≥3 significantly increased odds of liver injury (OR 9.19), hepatotoxicity (OR 35.95), and coagulopathy (OR 8.34).
  • Elevated risk persisted even with acetylcysteine administration within 8 hours.

Conclusions:

  • Massive paracetamol overdose patients face higher organ injury risk, irrespective of early acetylcysteine.
  • Patients with APAPpl:APAPt ≥3 require consideration for enhanced therapeutic strategies.
  • Further validation of novel biomarkers and abbreviated acetylcysteine regimens is needed for this cohort.